Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab

Blood (2025) 146 (Supplement 1): 3734.

https://doi.org/10.1182/blood-2025-3734

Published: 2025

Journal Articles

Characteristics and outcome of composite lymphomas: A synthetic cohort approach

Benedikt Pelzer, Sara Jennrich, Tudor-Mihai Magdas, Hans Christian Reinhardt, Bastian von Tresckow, Julia von Tresckow

Blood (2025) 146 (Supplement 1): 7098.

https://doi.org/10.1182/blood-2025-7098

Published: 2025

Journal Articles

Prognostic role of FDG-PET in outcomes of relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies

Sophie Wollnitza, David Ventura, Marcel Teichert, Fabian Freisleben, Hristo Boyadzhiev, Robert Seifert, Michelle Amon, Julia Scholz, Alexander Pohlmann, Akhil Behringer, Philipp Backhaus, Philipp Schindler, Wolfgang Roll, Fabian Müller, Thomas Pabst, Michael Schaefers, Bastian von Tresckow, Evgenii Shumilov, Georg Lenz

Blood (2025) 146 (Supplement 1): 5518.

https://doi.org/10.1182/blood-2025-5518

Published: 2025

Journal Articles

Pembro-CORE: Interim analysis of a phase II PET-adapted trial omitting high-dose chemotherapy with PD-1-based salvage in first-relapsed Hodgkin lymphoma

Hishan Tharmaseelan, Sarah Gillessen, Ina Bühnen, Carsten Kobe, Karin G. Schrenk, Prof. Dr. Max S Topp, Ulf Schnetzke, Nico Freund, Stephanie Sasse, Philipp Ernst, Tanja Zamrik, Wolfram Klapper, Michael Fuchs, Sven Borchmann, Paul Bröckelmann, Peter Borchmann, Bastian von Tresckow

Blood (2025) 146 (Supplement 1): 5401.

https://doi.org/10.1182/blood-2025-5401

Published: 2025

Journal Articles

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma

Blood (2025) 146 (Supplement 1): 61.

https://doi.org/10.1182/blood-2025-61

Published: 2025

Journal Articles

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Blood (2025) 146 (Supplement 1): 468.

https://doi.org/10.1182/blood-2025-468

Published: 2025

Journal Articles

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Blood (2025) 146 (Supplement 1): 669.

https://doi.org/10.1182/blood-2025-669

Published: 2025

Journal Articles

Shift toward more naïve phenotype of the T cell compartment in patients with aggressive B cell non-Hodgkin lymphoma undergoing high-dose methotrexate therapy

Vanessa Ridder, Keven Hoerster, Sophie Nickel, Philip Ridder, Marcel Teichert, Joe Puthenparambil, Hans Christian Reinhardt, Bastian von Tresckow

Blood (2025) 146 (Supplement 1): 4188.

https://doi.org/10.1182/blood-2025-4188

Published: 2025

Journal Articles

Machine learning-based body composition analysis for risk stratification in newly diagnosed diffuse large B cell lymphoma

Fabian Ullrich, René Hosch, Emre Kocakavuk, Hans Christian Reinhardt, Ulrich Dührsen, Andreas Hüttmann, Felix Nensa, Bastian von Tresckow

Blood (2025) 146 (Supplement 1): 897.

https://doi.org/10.1182/blood-2025-897

Published: 2025

Journal Articles

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

Blood (2025) 146 (Supplement 1): 4590.

https://doi.org/10.1182/blood-2025-4590

Published: 2025

Journal Articles

Efficacy and safety of vipor (P) in relapsed or refractory large B-cell lymphoma

Thomas Oellerich, Rebecca Wurm-Kuczera, Shashwat Sahay, Meng Wang, Salaheddine Ali, Nazli Serin, Khouloud Kouidri, Donika Tahiri, Sebastian Scheich, Uta Brunnberg, David Winkler, Samixa Pudasaini, Zoi Saxonis, Atef Abdelhafez, Tatiana Borodina, Ulrike Krueger, David Böckle, Corinna Leng, Joseph Kauer, Isabelle Krämer, Konstantinos Christofyllakis, Marcel Teichert, Niklas Gebauer, Ulf Schnetzke, Thomas Weber, Lukas Frenzel, Anna-Carina Hund, Evgenii Shumilov, Thomas Melchardt, Florian Eisele, Mirjeta Berisha, Jakob Rudzki, Christian Scholz, Martin Schmidt-Hieber, Dimitrios Mougiakakos, Johannes Duell, Gerald Wulf, Christian Schmidt, Georg Lenz, Bastian von Tresckow, Hans Christian Reinhardt, Richard Greil, Lorenz Thurner, Peter Dreger, Martin Dreyling, Christiane Pott, Martina Rudelius, Oliver Weigert, Phillipp Strubel, Roland Eils, Antonia Busse, Ulrich Keller, Naveed Ishaque, Björn Chapuy

Blood (2025) 146 (Supplement 1): 3688.

https://doi.org/10.1182/blood-2025-3688

Published: 2025

Journal Articles

Final analysis of the Phase III GHSG HD21 trial: PET-guided brecadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 152.

https://doi.org/10.1182/blood-2025-152

Published: 2025

Journal Articles

Early PET response for relapse prediction in 2nd or higher line lisocabtagen maraleucel in large B-cell lymphoma

Marcel Teichert, Simge Demirok, Fatma Yalinci, Stefan Alig, Keven Hoerster, Fabian Ullrich, Francesco Barbato, Ken Hermann, Hans Christian Reinhardt, Bastian von Tresckow

Blood (2025) 146 (Supplement 1): 4549.

https://doi.org/10.1182/blood-2025-4549

Published: 2025

Journal Articles

Brentuximab vedotin plus DHAP as effective salvage therapy in CD30+ peripheral T-cell lymphoma: A retrospective multicenter study

Thomas Weber, Sophy Denker, Julia Johanna Helmes, Susanne Ghandili, Kai Arne Plümer, Till Braun, Bastian von Tresckow, Ulrich Keller, Frederik Damm, Natali Pflug

Blood (2025) 146 (Supplement 1): 5425.

https://doi.org/10.1182/blood-2025-5425

Published: 2025

Journal Articles

Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis

Evgenii Shumilov, Débora-Michèle Grote Urtubey, Marcel Teichert, Maximilian Seib, Rebecca Wurm-Kuczera, Joseph Kauer, Friedrich-Linus Roessiger, Tobias Tix, Alexander Hölscher, Philipp Gödel, Christoph Brey, Paolo Mazzeo, Zoi Saxonis, Belana Kuhn, Vanja Zeremski, Franziska Brunner, Susanne Ghandili, Enver Aydilek, Markus Maulhardt, Philipp Nakov, Gregor Friedrich, Christian Schultze-Florey, Giuliano Filippini Velazquez, Igor Age Kos, Anna Ossami Saidy, Christoph Kimmich, Maika Klaiber-Hakimi, Philipp Berning, Andrea Kerkhoff, Bertram Glass, Isabelle Krämer, Lorenz Thurner, Mathias Lutz, Florian Heidel, Vladan Vucinic, Christiane Pott, Andreas Viardot, Gerald Wulf, Thomas Weber, Dimitrios Mougiakakos, Francis Ayuk, Udo Holtick, Sascha Dietrich, Niklas Gebauer, Ulf Schnetzke, Mathias Hänel, Martin Dreyling, Peter Dreger, Björn Chapuy, Fabian Müller, Bastian von Tresckow, Georg Lenz

Blood (2025) 146 (Supplement 1): 5473.

https://doi.org/10.1182/blood-2025-5473

Published: 2025

Journal Articles

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Blood (2025) 146 (14): 1677–1686.

https://doi.org/10.1182/blood.2025028330

Published: 2025

Includes: Supplemental data

Journal Articles

Checkpoint-primed allo-HCT in HL: cure gains, risk remains

Paul J. Bröckelmann, Bastian von Tresckow

Blood (2025) 146 (8): 911–912.

https://doi.org/10.1182/blood.2025029908

Published: 2025

Journal Articles

Combined targeted modality in cHL: a risky bet?

Paul J. Bröckelmann, Bastian von Tresckow

Blood (2025) 145 (3): 249–251.

https://doi.org/10.1182/blood.2024027360

Published: 2025

Journal Articles

Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies

Blood (2024) 144 (Supplement 1): 2088.

https://doi.org/10.1182/blood-2024-194525

Published: 2024

Journal Articles

PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial

Blood (2024) 144 (Supplement 1): 568.

https://doi.org/10.1182/blood-2024-207946

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab

Characteristics and outcome of composite lymphomas: A synthetic cohort approach

Prognostic role of FDG-PET in outcomes of relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies

Pembro-CORE: Interim analysis of a phase II PET-adapted trial omitting high-dose chemotherapy with PD-1-based salvage in first-relapsed Hodgkin lymphoma

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Shift toward more naïve phenotype of the T cell compartment in patients with aggressive B cell non-Hodgkin lymphoma undergoing high-dose methotrexate therapy

Machine learning-based body composition analysis for risk stratification in newly diagnosed diffuse large B cell lymphoma

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

Efficacy and safety of vipor (P) in relapsed or refractory large B-cell lymphoma

Final analysis of the Phase III GHSG HD21 trial: PET-guided brecadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma

Early PET response for relapse prediction in 2nd or higher line lisocabtagen maraleucel in large B-cell lymphoma

Brentuximab vedotin plus DHAP as effective salvage therapy in CD30+ peripheral T-cell lymphoma: A retrospective multicenter study

Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Checkpoint-primed allo-HCT in HL: cure gains, risk remains

Combined targeted modality in cHL: a risky bet?

PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only